Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Prostate Cancer

  Free Subscription


Articles published in Proc Natl Acad Sci U S A

Retrieve available abstracts of 22 articles:
HTML format



Single Articles


    December 2023
  1. SUSHENTSEV N, Hamm G, Richings J, McLean MA, et al
    Imaging tumor lactate is feasible for identifying intermediate-risk prostate cancer patients with postsurgical biochemical recurrence.
    Proc Natl Acad Sci U S A. 2023;120:e2312261120.
    PubMed     Abstract available


    November 2023
  2. MAJI S, Pradhan AK, Kumar A, Bhoopathi P, et al
    MDA-9/Syntenin in the tumor and microenvironment defines prostate cancer bone metastasis.
    Proc Natl Acad Sci U S A. 2023;120:e2307094120.
    PubMed     Abstract available


    August 2023
  3. WANG Z, Petricca J, Liu M, Zhang S, et al
    SETD7 functions as a transcription repressor in prostate cancer via methylating FOXA1.
    Proc Natl Acad Sci U S A. 2023;120:e2220472120.
    PubMed     Abstract available


    July 2023
  4. QIAO Y, Wotring JW, Zheng Y, Zhang CJ, et al
    Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response.
    Proc Natl Acad Sci U S A. 2023;120:e2221809120.
    PubMed     Abstract available


  5. CHEN X, Yang HT, Zhang B, Phillips JW, et al
    The RNA-binding proteins hnRNP H and F regulate splicing of a MYC-dependent HRAS exon in prostate cancer cells.
    Proc Natl Acad Sci U S A. 2023;120:e2220190120.
    PubMed     Abstract available


    May 2023
  6. SINGH R, Meng H, Shen T, Lumahan LEV, et al
    TRAF4-mediated nonproteolytic ubiquitination of androgen receptor promotes castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2023;120:e2218229120.
    PubMed     Abstract available


    April 2023
  7. ZHANG W, Lee AM, Jena S, Huang Y, et al
    Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modeling.
    Proc Natl Acad Sci U S A. 2023;120:e2218522120.
    PubMed     Abstract available


    January 2023
  8. THIYAGARAJAN T, Ponnusamy S, Hwang DJ, He Y, et al
    Inhibiting androgen receptor splice variants with cysteine-selective irreversible covalent inhibitors to treat prostate cancer.
    Proc Natl Acad Sci U S A. 2023;120:e2211832120.
    PubMed     Abstract available


    October 2022
  9. SHEN T, Dong B, Meng Y, Moore DD, et al
    A COP1-GATA2 axis suppresses AR signaling and prostate cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2205350119.
    PubMed     Abstract available


    September 2022
  10. SUN R, Wei T, Ding D, Zhang J, et al
    CYCLIN K down-regulation induces androgen receptor gene intronic polyadenylation, variant expression and PARP inhibitor vulnerability in castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2205509119.
    PubMed     Abstract available


    July 2022
  11. KORSEN JA, Gutierrez JA, Tully KM, Carter LM, et al
    Delta-like ligand 3-targeted radioimmunotherapy for neuroendocrine prostate cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2203820119.
    PubMed     Abstract available


    June 2022
  12. LEE J, Olivieri C, Ong C, Masterson LR, et al
    Raf Kinase Inhibitory Protein regulates the cAMP-dependent protein kinase signaling pathway through a positive feedback loop.
    Proc Natl Acad Sci U S A. 2022;119:e2121867119.
    PubMed     Abstract available


    May 2022
  13. BARATCHIAN M, Tiwari R, Khalighi S, Chakravarthy A, et al
    H3K9 methylation drives resistance to androgen receptor-antagonist therapy in prostate cancer.
    Proc Natl Acad Sci U S A. 2022;119:e2114324119.
    PubMed     Abstract available


    April 2022
  14. VAN HEIJSTER FHA, Breukels V, Jansen KCFJ, Schalken JA, et al
    Carbon sources and pathways for citrate secreted by human prostate cancer cells determined by NMR tracing and metabolic modeling.
    Proc Natl Acad Sci U S A. 2022;119:e2024357119.
    PubMed     Abstract available


    January 2022
  15. BAKHT MK, Hayward JJ, Shahbazi-Raz F, Skubal M, et al
    Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


  16. LIAO Y, Chen CH, Xiao T, de la Pena Avalos B, et al
    Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress.
    Proc Natl Acad Sci U S A. 2022;119.
    PubMed     Abstract available


    October 2021
  17. BELLO T, Paindelli C, Diaz-Gomez LA, Melchiorri A, et al
    Computational modeling identifies multitargeted kinase inhibitors as effective therapies for metastatic, castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    September 2021
  18. YOSHIHAMA Y, LaBella KA, Kim E, Bertolet L, et al
    AR-negative prostate cancer is vulnerable to loss of JMJD1C demethylase.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    August 2021

  19. Correction for Baek et al., Ligand-specific allosteric regulation of coactivator functions of androgen receptor in prostate cancer cells.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed    


  20. SHRESTHA E, Coulter JB, Guzman W, Ozbek B, et al
    Oncogenic gene fusions in nonneoplastic precursors as evidence that bacterial infection can initiate prostate cancer.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


  21. FENG W, Cao Z, Lim PX, Zhao H, et al
    Rapid interrogation of cancer cell of origin through CRISPR editing.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed     Abstract available


    March 2021
  22. WU WF, Wang L, Spetsieris N, Boukovala M, et al
    Estrogen receptor beta and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate.
    Proc Natl Acad Sci U S A. 2021;118:e2011269118.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.